DYNDyne Therapeutics, Inc.
$16.65+27% 1Y
$16.65
$12.3752 weeks$26.80
DYN as reported
- Net income
- −$519M
Net income · +26% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$480M
Free cash flow · +33% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.30
EPS · −15% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$519M | +26% | Q2 2026 |
| EPS | −$3.30 | −15% | Q2 2026 |
| ROE | −58% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
| ROIC | 4638% | n/a | Q2 2026 |
| Free cash flow | −$480M | +33% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Dyne Therapeutics, Inc. (DYN) · Net incomeNet incomeDyne Therapeutics, Inc. (DYN)
On our screens:Most shorted stocks